)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Whitehawk Therapeutics
Whitehawk Therapeutics (WHWK) investor relations material
Whitehawk Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
Three next-generation ADCs—HWK-007, HWK-016 and HWK-206—are in Phase 1 development; all three original programs advanced into clinical development within 12 months.
FYARRO was divested in March 2025; no product sales were recorded in Q3 or 9M 2026, leaving development-stage programs as the principal business focus.
Financial highlights
Q3 2026 net loss was $21.2M versus $17.7M in Q3 2025; 9M net loss was $60.0M versus net income of $2.7M, which included an $87.3M gain on sale of business.
Q3 revenue was $0 versus $0.9M in Q3 2025; 9M revenue was $0 versus $7.1M, reflecting the FYARRO divestiture.
Q3 operating expenses were $22.9M versus $19.5M; 9M operating expenses were $64.6M versus $96.7M, including the prior-year upfront license fee.
Cash, cash equivalents and short-term investments totaled $169.7M at September 30, 2026; 9M operating cash use was $56.4M versus $80.2M.
Outlook and guidance
Existing cash, cash equivalents and short-term investments are expected to fund planned operations into the second half of 2028; significant expenses and operating losses are expected to continue.
Initial Phase 1 data for HWK-007 and HWK-016 are expected in H1 2027; HWK-206 data are expected by year-end 2027.
First HWK-206 clinical sites in China are expected to activate in Q1 2027 following an IND submission; IND submissions for programs under the Hangzhou DAC and Biocytogen arrangements are anticipated starting in H2 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Whitehawk Therapeutics
- Advancing three next-gen ADCs in phase I, with key data expected in early 2027 and strong funding.WHWK
Morgan Stanley 24th Annual Global Healthcare Conference - Net loss of $38.8M in H1 2026; $190M cash; ADC pipeline advanced and cash runway extended.WHWKQ2 2026
- Advancing next-gen ADCs for high-value targets with strong clinical and financial momentum.WHWKCorporate presentation
- All proposals passed, with directors elected and auditor ratified; no questions were submitted.WHWKAGM 2026
- Three ADCs progress with unique technology, aiming for high efficacy and tolerability by 2027.WHWKJefferies Global Healthcare Conference 2026
- Registering 22.3M shares for resale after $87.5M private placement to fund ADC cancer pipeline.WHWKRegistration filing
- Next-gen ADCs targeting validated tumor markers advance toward clinic with strong capital support.WHWKFireside Chat
- PRECISION1's interim results show promise for TSC1/TSC2 tumor-agnostic therapy, with key data due soon.WHWKJefferies 2024 Global Healthcare Conference
- Pivoted to ADC oncology with robust funding and three INDs planned within 15 months.WHWKQ4 2024
Next Whitehawk Therapeutics earnings date
Q4 202610 Mar, 2027
Whitehawk Therapeutics
Next Whitehawk Therapeutics earnings date
Q4 202610 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aadi Bioscience Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers and other serious diseases. The company's lead product is designed to target specific mutations in the mTOR pathway, a key regulator of cell growth and survival. The company is headquartered in Pacific Palisades, California, and its shares are listed on the NASDAQ.